The present invention relates to a fusion protein comprising a cytokine antagonist and a targeting moiety preferably an antibody or anti body like molecule. In a preferred embodiment the cytokine antagonist is a modified cytokine which binds to the receptor but doesn t induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune or inflammation related disorders.